KYMR — Kymera Therapeutics Inc

Kymera Therapeutics Inc (KYMR) is a biotechnology company listed on NASDAQ. It is led by Nello Mainolfi M.D., Ph.D., based in 500 North Beacon Street, Watertown, MA, United States, 02472, with about 253 employees. Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Latest reported KYMR revenue for 2025-09-30 was $2.8M. Net income was -$224.4M. Revenue was down 75.9% from 2025-06-30 to 2025-09-30. KYMR currently screens at market cap $7.39B.

Use this KYMR page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the KYMR quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the KYMR SEC filings page. Lician reads the product cache first so this HTML stays unique to Kymera Therapeutics Inc even when a live quote feed is slow.